Provided by Tiger Trade Technology Pte. Ltd.

Tenaya Therapeutics Inc

0.6651
-0.0358-5.11%
Post-market: 0.66750.0024+0.36%19:49 EDT
Volume:2.29M
Turnover:1.56M
Market Cap:144.00M
PE:-1.12
High:0.7000
Open:0.6920
Low:0.6620
Close:0.7009
52wk High:2.35
52wk Low:0.3600
Shares:216.51M
Float Shares:205.84M
Volume Ratio:0.70
T/O Rate:1.11%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5922
EPS(LYR):-0.5922
ROE:-83.84%
ROA:-43.72%
PB:1.17
PE(LYR):-1.12

Loading ...

Tenaya Therapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
Dec 12, 2025

Tenaya Therapeutics Announces Pricing of Public Offering

THOMSON REUTERS
·
Dec 12, 2025

BUZZ-Tenaya Therapeutics slides after launching stock offering

Reuters
·
Dec 12, 2025

BRIEF-Tenaya Therapeutics says early trial shows promise for gene therapy in rare heart condition

Reuters
·
Dec 12, 2025

Tenaya Therapeutics Announces Proposed Public Offering

GlobeNewswire
·
Dec 12, 2025

FDA Lifts Clinical Hold on Tenaya Therapeutics’ MyPEAK-1 Trial

Reuters
·
Dec 12, 2025

Tenaya Therapeutics Reports Positive Interim Results for TN-401 Gene Therapy in ARVC Trial

Reuters
·
Dec 12, 2025

Tenaya Therapeutics Announces Rapid Resolution and Lifting of Clinical Hold for Mypeak-1™ Phase 1B/2a Clinical Trial of Tn-201 Gene Therapy

THOMSON REUTERS
·
Dec 12, 2025

Tenaya Therapeutics Inc - Does Not Expect Hold to Impact Data Milestones

THOMSON REUTERS
·
Dec 12, 2025

Tenaya Therapeutics Inc - Tn-401 Well Tolerated at 3E13 Vg/Kg Dose

THOMSON REUTERS
·
Dec 12, 2025

Tenaya Therapeutics Inc: Robust Transduction and Demonstrated Increases in Pkp2 Protein Levels in First Two Patients at Week 8

THOMSON REUTERS
·
Dec 12, 2025

Tenaya Therapeutics Inc - Meaningful Reductions in Arrhythmia Burden Observed in First Two Patients With More Than Six Months of Follow-up

THOMSON REUTERS
·
Dec 12, 2025

Tenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults with PKP2-associated ARVC

GlobeNewswire
·
Dec 12, 2025

Tenaya Therapeutics Inc - FDA Places Clinical Hold On Tenaya's Mypeak-1 Trial - SEC Filing

Reuters
·
Nov 20, 2025

LifeSci Capital Reaffirms Their Buy Rating on Tenaya Therapeutics (TNYA)

TIPRANKS
·
Nov 15, 2025

Tenaya Therapeutics (TNYA) Receives a Buy from Morgan Stanley

TIPRANKS
·
Nov 11, 2025

Chardan Capital Reaffirms Their Buy Rating on Tenaya Therapeutics (TNYA)

TIPRANKS
·
Nov 11, 2025

Tenaya Therapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
Nov 11, 2025

Promising Outlook for Tenaya Therapeutics’ TN-201 Program Despite Procedural Clinical Hold

TIPRANKS
·
Nov 11, 2025

Tenaya Therapeutics Shares Reverse Premarket Course, Last up 2.1%

THOMSON REUTERS
·
Nov 10, 2025